EP1772452 - Matrix metalloproteinase inhibitors and uses thereof [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 06.06.2008 Database last updated on 02.09.2024 | Most recent event Tooltip | 03.10.2008 | Change - representative | published on 05.11.2008 [2008/45] | Applicant(s) | For all designated states Bristol-Myers Squibb Pharma Company P.O. Box 4000 Princeton NJ 08543-4000 / US | [2008/37] |
Former [2007/15] | For all designated states Bristol-Myers Squibb Pharma Company PO Box 4000 Princeton New Jersey 08443-4000 / US | Inventor(s) | 01 /
Decicco, Carl P. 102 Indian Springs Road Kennett Square, PA 19348 / US | 02 /
Nelson, David J. 40 Tiverton Circle Newark, DE 19702 / US | 03 /
Barrett, John A. 46 Fox Run Groton, MA 01450 / US | 04 /
Carpenter, Alan P. 73 Cranberry Hill Lane Carlisle, MA 01741 / US | 05 /
Duran, James J. 17 Springbrook Lane Newark, DE 19711 / US | 06 /
Rajopadhye, Milind 21 Honeysuckle Road Wedstford, MA 01886 / US | [2007/15] | Representative(s) | Howard, Paul Nicholas, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
Former [2008/45] | Howard, Paul Nicholas, et al Carpmaels & Ransford 43-45 Bloomsbury Square London WC1A 2RA / GB | ||
Former [2007/15] | Howard, Paul Nicholas, et al Carpmaels & Ransford, 43-45 Bloomsbury Square London WC1A 2RA / GB | Application number, filing date | 06076915.5 | 15.02.2001 | [2007/15] | Priority number, date | US20000182627P | 15.02.2000 Original published format: US 182627 P | [2007/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | EP1772452 | Date: | 11.04.2007 | Language: | EN | [2007/15] | Type: | A3 Search report | No.: | EP1772452 | Date: | 04.07.2007 | [2007/27] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 01.06.2007 | Classification | IPC: | C07D413/12, C07D267/00, C07D401/12, C07D401/14, C07F9/09, A61K31/395, A61K31/4427, A61K31/661, A61K51/04, A61P35/00, A61P29/00 | [2007/22] | CPC: |
A61K49/14 (EP,US);
A61K49/0002 (EP,US);
A61K49/085 (EP,US);
A61K49/10 (EP,US);
A61K51/088 (EP,US);
A61P29/00 (EP);
A61P35/00 (EP);
C07D207/26 (EP,US);
C07D213/82 (EP,US);
C07D267/00 (EP,US);
C07D401/12 (EP,US);
C07D401/14 (EP,US);
|
Former IPC [2007/15] | C07D401/12, C07D413/12, C07D267/00, C07D401/14, C07F9/09, A61K31/395, A61K31/4427, A61K31/661, A61K51/04 | Designated contracting states | [2008/11] |
Former [2007/15] | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR | Title | German: | Matrix-Metalloproteinaseinhibitoren und deren Verwendung | [2007/15] | English: | Matrix metalloproteinase inhibitors and uses thereof | [2007/15] | French: | Inhibiteurs de métalloprotéase matricielle et utilisation de ceux-ci | [2007/15] | Examination procedure | 05.01.2008 | Application deemed to be withdrawn, date of legal effect [2008/28] | 13.02.2008 | Despatch of communication that the application is deemed to be withdrawn, reason: examination fee not paid in time [2008/28] | Parent application(s) Tooltip | EP01912751.3 / EP1257549 | Fees paid | Renewal fee | 23.10.2006 | Renewal fee patent year 03 | 23.10.2006 | Renewal fee patent year 04 | 23.10.2006 | Renewal fee patent year 05 | 23.10.2006 | Renewal fee patent year 06 | 23.10.2006 | Renewal fee patent year 07 | Penalty fee | Additional fee for renewal fee | 29.02.2008 | 08   M06   Not yet paid |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]EP0649658 (UNIV LELAND STANFORD JUNIOR [US]) [Y] 1,47,60,65-67,75-77 * the whole document *; | [Y]WO9718207 (DU PONT MERCK PHARMA [US]) [Y] 1,4-8,10,20,28,29,47,48,51-56,60,61,68-74,78 * page 44, line 1 - page 48, line 20; example 1(k); table I; page 280, line 1 - page 281, line 30 *; | [XY]WO9847541 (NYCOMED IMAGING AS [NO], et al) [X] 1,4-7,10,11,20,21,23,28,32,34,47,48,51-56,60,61,68-74,78 * pages 1-10, 25-28, 32-70; examples 1, 3 * * pages 1-10, 25-28, 32-70 * [Y] 1-10,20-22,24-31,33,35-38,47,48,51-56,60-78; | [Y]WO9918074 (DU PONT PHARM CO [US]) [Y] 1,4-7,10,20,28,30,47,48,51-56,60,61,68-74,78 * page 4, line 14 - page 13, line 37; examples 65, 119; page 271, line 1 - page 272, line 22 *; | [Y]WO9958162 (DU PONT PHARM CO [US]) [Y] 1,20-22,24,25,27,28,33,35,36,38,60-64 * page 73, line 25 - page 86, line 12; examples *; | [Y]WO9965867 (DU PONT PHARM CO [US]) [Y] 1-7,9,10,20,28,31,47,48,51-56,60,61,68-74,78 * page 4, line 21 - page 19, line 35; table 8; page 176, line 1 - page 177, line 29 *; | [Y] - M. RAJOPADHYE ET AL, BIOORG. MED. CHEM. LETT., (1996), vol. 6, no. 15, pages 1737 - 1740, XP004135593 [Y] 1,20,21,26,28,37 * the whole document * DOI: http://dx.doi.org/10.1016/0960-894X(96)00264-8 | [X] - MACPHERSON L J ET AL, "Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (199708), vol. 40, no. 16, ISSN 0022-2623, pages 2525 - 2532, XP002099324 [X] 1-79 * Tables 1 and 3 * DOI: http://dx.doi.org/10.1021/jm960871c | [X] - LEVY E ET AL, "Matrix Metalloproteinase Inhibitors: A Structure-Activity Study", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1998), vol. 41, no. 2, ISSN 0022-2623, pages 199 - 223, XP002115860 [X] 1-79 * Tables 2,8,10-15; Compounds 6a-6kkk * DOI: http://dx.doi.org/10.1021/jm970494j | [X] - BECKETT R P ET AL, "RECENT ADVANCES IN MATRIX METALLOPROTEINASE INHIBITOR RESEARCH", DDT - DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD, GB, (199601), vol. 1, no. 1, ISSN 1359-6446, pages 16 - 26, XP002043033 [X] 1-79 * Compounds 1-2,7-9,11-17,21-25 * DOI: http://dx.doi.org/10.1016/1359-6446(96)89115-X | [X] - LOWE C, "Tumour necrosis factor-[alpha] antagonists and their therapeutic applications", EXPERT OPINION ON THERAPEUTIC PATENTS 1998 UNITED KINGDOM, (1998), vol. 8, no. 10, ISSN 1354-3776, pages 1309 - 1322, XP002430630 [X] 1-79 * compounds 18-41, 47; p. 1312-1315 * DOI: http://dx.doi.org/10.1517/13543776.8.10.1309 | [X] - LEUNG D ET AL, "Protease inhibitors: Current status and future prospects", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (20000210), vol. 43, no. 3, ISSN 0022-2623, pages 305 - 341, XP002254336 [X] 1-79 * Point 5.4; compounds 128, 130-135, 138-141 * DOI: http://dx.doi.org/10.1021/jm990412m | [X] - BARLAAM B ET AL, "NEW ALPHA-SUBSTITUTED SUCCINATE-BASED HYDROXAMIC ACIDS AS TNFALPHA CONVERTASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, (1999), vol. 42, no. 23, ISSN 0022-2623, pages 4890 - 4908, XP000974275 [X] 1-79 * Compounds 1-6, 6a-6n, 12,22; tables 2-3 * DOI: http://dx.doi.org/10.1021/jm990377j | [X] - BECKETT R P ET AL, "Matrix metalloproteinase inhibitors 1998", EXPERT OPINION ON THERAPEUTIC PATENTS 1998 UNITED KINGDOM, (1998), vol. 8, no. 3, ISSN 1354-3776, pages 259 - 282, XP002430631 [X] 1-79 * Compounds 1-43,47-51 * DOI: http://dx.doi.org/10.1517/13543776.8.3.259 |